Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
- 1 August 2006
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (12), 1875-1880
- https://doi.org/10.1016/j.ejca.2006.03.015
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group StudyJournal of Clinical Oncology, 2005
- mTOR-targeted therapy of cancer with rapamycin derivativesAnnals Of Oncology, 2005
- Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2004
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−miceProceedings of the National Academy of Sciences, 2001
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- Interstitial Pneumonitis Associated with Sirolimus Therapy in Renal-Transplant RecipientsNew England Journal of Medicine, 2000